{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T22:31:13Z","timestamp":1792017073532,"version":"4.4.0"},"reference-count":70,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2025,4,12]],"date-time":"2025-04-12T00:00:00Z","timestamp":1744416000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Rift Valley fever virus (RVFV) is a mosquito-transmitted bunyavirus that can cause substantial morbidity and mortality in livestock and humans, for which there are no currently available licensed human therapeutics or vaccines. Therefore, the development of safe and effective antivirals is both necessary and urgent. The Gc protein is the primary target of the neutralizing antibody response related to Rift Valley fever virus. Here, we report one Gc-specific neutralizing antibody (NA137) isolated from an alpaca and one bispecific antibody (E2-NA137), the protective efficacies of which we evaluated in A129 mice. In this prophylactic study, the survival rates of the NA137 and E2-NA137 groups were both 80%, and in the treatment study, the survival rates were 20% and 60%, respectively. Altogether, our results emphasize that NA137 and E2-NA137 provide a potential approach for treating RVFV either prophylactically or therapeutically.<\/jats:p>","DOI":"10.3390\/v17040559","type":"journal-article","created":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T07:42:01Z","timestamp":1744616521000},"page":"559","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Screening of Neutralizing Antibodies Targeting Gc Protein of RVFV"],"prefix":"10.3390","volume":"17","author":[{"given":"Chuanyi","family":"Zhao","sequence":"first","affiliation":[{"name":"School of Medicine, Zhejiang University, Hangzhou 310058, China"},{"name":"Laboratory of Advanced Biotechnology, Beijing Institute of Biotechnology, Beijing 100071, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Hao","sequence":"additional","affiliation":[{"name":"Laboratory of Advanced Biotechnology, Beijing Institute of Biotechnology, Beijing 100071, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Bian","sequence":"additional","affiliation":[{"name":"Laboratory of Advanced Biotechnology, Beijing Institute of Biotechnology, Beijing 100071, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6615-4825","authenticated-orcid":false,"given":"Xiaofan","family":"Zhao","sequence":"additional","affiliation":[{"name":"Laboratory of Advanced Biotechnology, Beijing Institute of Biotechnology, Beijing 100071, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangyang","family":"Chi","sequence":"additional","affiliation":[{"name":"Laboratory of Advanced Biotechnology, Beijing Institute of Biotechnology, Beijing 100071, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2869-1467","authenticated-orcid":false,"given":"Zhengshan","family":"Chen","sequence":"additional","affiliation":[{"name":"Laboratory of Advanced Biotechnology, Beijing Institute of Biotechnology, Beijing 100071, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangcheng","family":"Fu","sequence":"additional","affiliation":[{"name":"Laboratory of Advanced Biotechnology, Beijing Institute of Biotechnology, Beijing 100071, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Zhu","sequence":"additional","affiliation":[{"name":"Laboratory of Advanced Biotechnology, Beijing Institute of Biotechnology, Beijing 100071, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Fang","sequence":"additional","affiliation":[{"name":"Laboratory of Advanced Biotechnology, Beijing Institute of Biotechnology, Beijing 100071, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changming","family":"Yu","sequence":"additional","affiliation":[{"name":"Laboratory of Advanced Biotechnology, Beijing Institute of Biotechnology, Beijing 100071, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2827-2185","authenticated-orcid":false,"given":"Jianmin","family":"Li","sequence":"additional","affiliation":[{"name":"Laboratory of Advanced Biotechnology, Beijing Institute of Biotechnology, Beijing 100071, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5805-2469","authenticated-orcid":false,"given":"Wei","family":"Chen","sequence":"additional","affiliation":[{"name":"School of Medicine, Zhejiang University, Hangzhou 310058, China"},{"name":"Laboratory of Advanced Biotechnology, Beijing Institute of Biotechnology, Beijing 100071, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,4,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1099\/jgv.0.001296","article-title":"Rift Valley fever: Biology and epidemiology","volume":"100","author":"Wright","year":"2019","journal-title":"J. Gen. Virol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"11152","DOI":"10.1128\/JVI.01519-08","article-title":"Multiple virus lineages sharing recent common ancestry were associated with a Large Rift Valley fever outbreak among livestock in Kenya during 2006\u20132007","volume":"82","author":"Bird","year":"2008","journal-title":"J. Virol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"493","DOI":"10.3390\/v3050493","article-title":"The pathogenesis of Rift Valley fever","volume":"3","author":"Ikegami","year":"2011","journal-title":"Viruses"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1007\/s11684-017-0596-6","article-title":"Human monoclonal antibodies as candidate therapeutics against emerging viruses","volume":"11","author":"Jin","year":"2017","journal-title":"Front. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1017\/S0950268810001020","article-title":"Rift Valley fever in Kenya: History of epizootics and identification of vulnerable districts","volume":"139","author":"Murithi","year":"2011","journal-title":"Epidemiol. Infect."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1086\/378747","article-title":"Rift Valley fever epidemic in Saudi Arabia: Epidemiological, clinical, and laboratory characteristics","volume":"37","author":"Madani","year":"2003","journal-title":"Clin. Infect. Dis."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Samy, A.M., Peterson, A.T., and Hall, M. (2017). Phylogeography of Rift Valley Fever Virus in Africa and the Arabian Peninsula. PLoS Negl. Trop. Dis., 11.","DOI":"10.1371\/journal.pntd.0005226"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e4","DOI":"10.1038\/emi.2016.136","article-title":"The first imported case of Rift Valley fever in China reveals a genetic reassortment of different viral lineages","volume":"6","author":"Liu","year":"2017","journal-title":"Emerg. Microbes Infect."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"5520","DOI":"10.1016\/j.vaccine.2015.08.020","article-title":"Rift Valley fever virus: A review of diagnosis and vaccination, and implications for emergence in Europe","volume":"33","author":"Mansfield","year":"2015","journal-title":"Vaccine"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1007\/s00705-019-04253-6","article-title":"Taxonomy of the order Bunyavirales: Update 2019","volume":"164","author":"Abudurexiti","year":"2019","journal-title":"Arch. Virol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1007\/s00705-018-04127-3","article-title":"Taxonomy of the order Bunyavirales: Second update 2018","volume":"164","author":"Maes","year":"2019","journal-title":"Arch. Virol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1073\/pnas.1217780110","article-title":"Crystal structure of glycoprotein C from Rift Valley fever virus","volume":"110","author":"Dessau","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"7154","DOI":"10.1073\/pnas.1603827113","article-title":"Structure of a phleboviral envelope glycoprotein reveals a consolidated model of membrane fusion","volume":"113","author":"Halldorsson","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e01558-17","DOI":"10.1128\/JVI.01558-17","article-title":"The Postfusion Structure of the Heartland Virus Gc Glycoprotein Supports Taxonomic Separation of the Bunyaviral Families Phenuiviridae and Hantaviridae","volume":"92","author":"Zhu","year":"2018","journal-title":"J. Virol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1126\/science.aal2712","article-title":"A glycerophospholipid-specific pocket in the RVFV class II fusion protein drives target membrane insertion","volume":"358","author":"Atkovska","year":"2017","journal-title":"Science"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"3486","DOI":"10.1016\/j.cell.2021.05.001","article-title":"Protective neutralizing antibodies from human survivors of Crimean-Congo hemorrhagic fever","volume":"184","author":"Fels","year":"2021","journal-title":"Cell"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/s41467-017-02789-2","article-title":"Shielding and activation of a viral membrane fusion protein","volume":"9","author":"Halldorsson","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Faburay, B., LaBeaud, A.D., McVey, D.S., Wilson, W.C., and Richt, J.A. (2017). Current Status of Rift Valley Fever Vaccine Development. Vaccines, 5.","DOI":"10.3390\/vaccines5030029"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1099\/0022-1317-75-6-1345","article-title":"Rift valley fever virus L segment: Correction of the sequence and possible functional role of newly identified regions conserved in RNA-dependent polymerases","volume":"75","author":"Poch","year":"1994","journal-title":"J. Gen. Virol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"13642","DOI":"10.1128\/JVI.01973-12","article-title":"Acid-activated structural reorganization of the Rift Valley fever virus Gc fusion protein","volume":"86","author":"Kortekaas","year":"2012","journal-title":"J. Virol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"10341","DOI":"10.1128\/JVI.01191-08","article-title":"Three-dimensional organization of Rift Valley fever virus revealed by cryoelectron tomography","volume":"82","author":"Freiberg","year":"2008","journal-title":"J. Virol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3762","DOI":"10.1128\/JVI.02483-08","article-title":"Electron cryo-microscopy and single-particle averaging of Rift Valley fever virus: Evidence for GN-GC glycoprotein heterodimers","volume":"83","author":"Huiskonen","year":"2009","journal-title":"J. Virol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"E7564","DOI":"10.1073\/pnas.1705176114","article-title":"Structures of phlebovirus glycoprotein Gn and identification of a neutralizing antibody epitope","volume":"114","author":"Wu","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/0923-2516(91)90069-F","article-title":"Antigenic analysis of Pdft Valley fever virus isolates: Monoclona|antibodies distinguish between wild-type and neurotropic virus strains","volume":"142","author":"Besselaar","year":"1991","journal-title":"Res. Virol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0923-2516(07)80002-1","article-title":"The effect of neutralizing monoclonai antibodies on early events in Rift Valley fever virus infectivity","volume":"145","author":"Besselaar","year":"1994","journal-title":"Res. Virol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/BF01309641","article-title":"The synergistic neutralization of Rift Valley fever virus by monoclonal antibodies to the envelope glycoproteins","volume":"125","author":"Besselaar","year":"1992","journal-title":"Arch. Virol."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Kitandwe, P.K., McKay, P.F., Kaleebu, P., and Shattock, R.J. (2022). An Overview of Rift Valley Fever Vaccine Development Strategies. Vaccines, 10.","DOI":"10.3390\/vaccines10111794"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1038\/s41564-019-0411-z","article-title":"Neutralization mechanism of human monoclonal antibodies against Rift Valley fever virus","volume":"4","author":"Wang","year":"2019","journal-title":"Nat. Microbiol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e2025642118","DOI":"10.1073\/pnas.2025642118","article-title":"Potent neutralization of Rift Valley fever virus by human monoclonal antibodies through fusion inhibition","volume":"118","author":"Chapman","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Eden, T., Menzel, S., Wesolowski, J., Bergmann, P., Nissen, M., Dubberke, G., Seyfried, F., Albrecht, B., Haag, F., and Koch-Nolte, F. (2017). A cDNA Immunization Strategy to Generate Nanobodies against Membrane Proteins in Native Conformation. Front. Immunol., 8.","DOI":"10.3389\/fimmu.2017.01989"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s00430-009-0116-7","article-title":"Single domain antibodies: Promising experimental and therapeutic tools in infection and immunity","volume":"198","author":"Wesolowski","year":"2009","journal-title":"Med. Microbiol. Immunol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1146\/annurev-biochem-063011-092449","article-title":"Nanobodies: Natural single-domain antibodies","volume":"82","author":"Muyldermans","year":"2013","journal-title":"Annu. Rev. Biochem."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"4586","DOI":"10.1073\/pnas.0505379103","article-title":"Molecular basis for the preferential cleft recognition by dromedary heavy-chain antibodies","volume":"103","author":"Silence","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Arbabi-Ghahroudi, M. (2017). Camelid Single-Domain Antibodies: Historical Perspective and Future Outlook. Front. Immunol., 8.","DOI":"10.3389\/fimmu.2017.01589"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"4764","DOI":"10.1096\/fj.14-253369","article-title":"A novel platform for engineering blood-brain barrier-crossing bispecific biologics","volume":"28","author":"Farrington","year":"2014","journal-title":"FASEB J."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Li, T., Qi, S., Unger, M., Hou, Y.N., Deng, Q.W., Liu, J., Lam, C.M.C., Wang, X.W., Xin, D., and Zhang, P. (2016). Immuno-targeting the multifunctional CD38 using nanobody. Sci. Rep., 6.","DOI":"10.1038\/srep27055"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/nchem.2811","article-title":"Cell-permeable nanobodies for targeted immunolabelling and antigen manipulation in living cells","volume":"9","author":"Herce","year":"2017","journal-title":"Nat. Chem."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"3559","DOI":"10.1182\/blood-2010-07-296749","article-title":"Inhibition of the Nef regulatory protein of HIV-1 by a single-domain antibody","volume":"117","author":"Bouchet","year":"2011","journal-title":"Blood"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"105446","DOI":"10.1016\/j.antiviral.2022.105446","article-title":"Inhibition of Chikungunya virus early replication by intracellular nanoantibodies targeting nsP2 Epitope Rich Region","volume":"208","author":"Deng","year":"2022","journal-title":"Antivir. Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e00837-18","DOI":"10.1128\/JVI.00837-18","article-title":"A Novel Nanobody Targeting Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Receptor-Binding Domain Has Potent Cross-Neutralizing Activity and Protective Efficacy against MERS-CoV","volume":"92","author":"Zhao","year":"2018","journal-title":"J. Virol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.chom.2020.04.023","article-title":"Identification of Human Single-Domain Antibodies against SARS-CoV-2","volume":"27","author":"Wu","year":"2020","journal-title":"Cell Host Microbe"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa1806311","article-title":"Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura","volume":"380","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s40265-022-01821-0","article-title":"Ozoralizumab: First Approval","volume":"83","author":"Keam","year":"2023","journal-title":"Drugs"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/s41573-019-0028-1","article-title":"Bispecific antibodies: A mechanistic review of the pipeline","volume":"18","author":"Labrijn","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1080\/21645515.2016.1251536","article-title":"Bispecific antibodies for viral immunotherapy","volume":"13","author":"Nyakatura","year":"2017","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"100083","DOI":"10.1016\/j.jve.2022.100083","article-title":"Bispecific antibody-derived molecules to target persistent HIV infection","volume":"8","author":"Nordstrom","year":"2022","journal-title":"J. Virus Erad."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Frei, J.C., Nyakatura, E.K., Zak, S.E., Bakken, R.R., Chandran, K., Dye, J.M., and Lai, J.R. (2016). Bispecific Antibody Affords Complete Post-Exposure Protection of Mice from Both Ebola (Zaire) and Sudan Viruses. Sci. Rep., 6.","DOI":"10.1038\/srep19193"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.virol.2021.01.009","article-title":"A human bispecific neutralization antibody against four serotypes of dengue virus","volume":"558","author":"Wang","year":"2021","journal-title":"Virology"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2373307","DOI":"10.1080\/22221751.2024.2373307","article-title":"A novel bispecific antibody targeting two overlapping epitopes in RBD improves neutralizing potency and breadth against SARS-CoV-2","volume":"13","author":"Sun","year":"2024","journal-title":"Emerg. Microbes Infect."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"e2200932","DOI":"10.1002\/smtd.202200932","article-title":"An Engineered IgG-VHH Bispecific Antibody against SARS-CoV-2 and Its Variants","volume":"6","author":"Chi","year":"2022","journal-title":"Small Methods"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"eabj5413","DOI":"10.1126\/scitranslmed.abj5413","article-title":"Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern","volume":"13","author":"Cho","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41421-022-00463-6","article-title":"Combating the SARS-CoV-2 Omicron (BA.1) and BA.2 with potent bispecific antibodies engineered from non-Omicron neutralizing antibodies","volume":"8","author":"Wang","year":"2022","journal-title":"Cell Discov."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2933","DOI":"10.1128\/JVI.80.6.2933-2940.2006","article-title":"Rescue of infectious rift valley fever virus entirely from cDNA, analysis of virus lacking the NSs gene, and expression of a foreign gene","volume":"80","author":"Ikegami","year":"2006","journal-title":"J. Virol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1038\/s41541-023-00763-2","article-title":"A Rift Valley fever mRNA vaccine elicits strong immune responses in mice and rhesus macaques","volume":"8","author":"Bian","year":"2023","journal-title":"NPJ Vaccines"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jviromet.2017.06.001","article-title":"A novel highly sensitive, rapid and safe Rift Valley fever virus neutralization test","volume":"248","author":"Paweska","year":"2017","journal-title":"J. Virol. Methods"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.cell.2020.06.034","article-title":"The Global Phosphorylation Landscape of SARS-CoV-2 Infection","volume":"182","author":"Bouhaddou","year":"2020","journal-title":"Cell"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"e52716","DOI":"10.7554\/eLife.52716","article-title":"Multimeric single-domain antibody complexes protect against bunyavirus infections","volume":"9","author":"Harmsen","year":"2020","journal-title":"eLife"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"3506","DOI":"10.1128\/JCM.00936-07","article-title":"Highly sensitive and broadly reactive quantitative reverse transcription-PCR assay for high-throughput detection of Rift Valley fever virus","volume":"45","author":"Bird","year":"2007","journal-title":"J. Clin. Microbiol."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Reed, C., Lin, K., Wilhelmsen, C., Friedrich, B., Nalca, A., Keeney, A., Donnelly, G., Shamblin, J., Hensley, L.E., and Olinger, G. (2013). Aerosol exposure to Rift Valley fever virus causes earlier and more severe neuropathology in the murine model, which has important implications for therapeutic development. PLoS Negl. Trop. Dis., 7.","DOI":"10.1371\/journal.pntd.0002156"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"3168","DOI":"10.1128\/AAC.00356-07","article-title":"In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections","volume":"51","author":"Gowen","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Caroline, A.L., Powell, D.S., Bethel, L.M., Oury, T.D., Reed, D.S., and Hartman, A.L. (2014). Broad spectrum antiviral activity of favipiravir (T-705): Protection from highly lethal inhalational Rift Valley Fever. PLoS Negl. Trop. Dis., 8.","DOI":"10.1371\/journal.pntd.0002790"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.antiviral.2014.01.016","article-title":"Favipiravir (T-705) protects against peracute Rift Valley fever virus infection and reduces delayed-onset neurologic disease observed with ribavirin treatment","volume":"104","author":"Scharton","year":"2014","journal-title":"Antivir. Res."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Hao, M., Zhang, G., Zhang, S., Chen, Z., Chi, X., Dong, Y., Fan, P., Liu, Y., Chen, Y., and Song, X. (2020). Characterization of Two Neutralizing Antibodies against Rift Valley Fever Virus Gn Protein. Viruses, 12.","DOI":"10.3390\/v12030259"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"3750","DOI":"10.1016\/j.celrep.2018.12.001","article-title":"A Protective Monoclonal Antibody Targets a Site of Vulnerability on the Surface of Rift Valley Fever Virus","volume":"25","author":"Allen","year":"2018","journal-title":"Cell Rep."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Gutjahr, B., Keller, M., Rissmann, M., von Arnim, F., Jackel, S., Reiche, S., Ulrich, R., Groschup, M.H., and Eiden, M. (2020). Two monoclonal antibodies against glycoprotein Gn protect mice from Rift Valley Fever challenge by cooperative effects. PLoS Negl. Trop. Dis., 14.","DOI":"10.1371\/journal.pntd.0008143"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"e0055621","DOI":"10.1128\/mSphere.00556-21","article-title":"Isotype-Specific Fc Effector Functions Enhance Antibody-Mediated Rift Valley Fever Virus Protection In Vivo","volume":"6","author":"Cartwright","year":"2021","journal-title":"mSphere"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1128\/JVI.02095-06","article-title":"Complete genome analysis of 33 ecologically and biologically diverse Rift Valley fever virus strains reveals widespread virus movement and low genetic diversity due to recent common ancestry","volume":"81","author":"Bird","year":"2007","journal-title":"J. Virol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.chom.2011.06.007","article-title":"DC-SIGN as a receptor for phleboviruses","volume":"10","author":"Lozach","year":"2011","journal-title":"Cell Host Microbe"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.virol.2009.02.038","article-title":"Single-particle cryo-electron microscopy of Rift Valley fever virus","volume":"387","author":"Sherman","year":"2009","journal-title":"Virology"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"e2400163121","DOI":"10.1073\/pnas.2400163121","article-title":"Bispecific antibodies targeting two glycoproteins on SFTSV exhibit synergistic neutralization and protection in a mouse model","volume":"121","author":"Chang","year":"2024","journal-title":"Proc. Natl. Acad. Sci. USA"}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/17\/4\/559\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:13:28Z","timestamp":1760030008000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/17\/4\/559"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,12]]},"references-count":70,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,4]]}},"alternative-id":["v17040559"],"URL":"https:\/\/doi.org\/10.3390\/v17040559","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,12]]}}}